C2N Diagnostics, LLC — Form D/A
C2N Diagnostics, LLC of ST. LOUIS, MO, a company, filed a Form D amendment with the SEC on 2024-09-26. The offering totals $25.0M, of which $25.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-09-26
- Form: D/A
- Accession: 0002021597-24-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $25.0M
- Amount sold: $25.0M
- Investors: 3
- Date of first sale: 2024-03-01
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-512447
Issuer
- Name: C2N Diagnostics, LLC
- CIK: 0002021597
- Entity type: Limited Liability Company
- Jurisdiction: DELAWARE
- Address: 4340 DUNCAN AVENUE, ST. LOUIS, MO, 63110
- Phone: 877-226-3424
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Fred Miller | Director | St. Louis, MO |
| Dr. Michael Goldblatt | Director | St. Louis, MO |
| Micah Onixt | Executive Officer | St. Louis, MO |
| Dr. David Holtzman | Director | St. Louis, MO |
| Dr. Randall Bateman | Director | St. Louis, MO |
| Dr. Joel Braunstein | Director | St. Louis, MO |
| Dr. Joel Braunstein | Executive Officer | St. Louis, MO |
Other filings by this issuer (2)
More